CF PharmTech, Inc. executed an on-market buyback of 89,300 H-shares on 8 October 2026, paying an aggregate HKD 0.50 million. The shares were repurchased within a price range of HKD 5.425 to HKD 5.83, giving a volume-weighted average of HKD 5.5946 per share. All repurchased shares have been retained as treasury stock.

Following the transaction: • Issued shares outstanding (excluding treasury shares) declined by 0.0277% to 321.86 million. • Treasury stock rose to 2.11 million shares. • Total issued share capital remained unchanged at 323.97 million shares, as the repurchased shares have not been cancelled.

The buyback was conducted under the general mandate approved on 26 June 2026, which authorises the company to repurchase up to 30.08 million shares. Cumulative purchases under this mandate now total 716,800 shares, equivalent to 0.24% of the issued shares on the mandate date.

In accordance with Hong Kong listing rules, CF PharmTech is subject to a moratorium on issuing new shares or disposing of treasury shares until 7 November 2026.